Transient marked elevation of serum CA 19-9 levels in a patient with acute cholangitis and biliary stent

Southern Medical Journal

Volumn 101, Issue 6, 2008, Pages 661-

  Chintanaboina, Jayakrishna ^a   Badari, Ambuga R ^a   Gopavaram, Deepa ^a   Qazi, Khalid J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CA 19-9 ANTIGEN; URSODEOXYCHOLIC ACID; TUMOR MARKER;

ACUTE CHOLANGITIS; ACUTE DISEASE; AGED; BILE DUCT; CANCER SURVIVAL; CASE REPORT; CAUCASIAN; CHOLANGITIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE INCREASE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EPIGASTRIC PAIN; FEVER; HOSPITAL READMISSION; HUMAN; INTESTINE TRANSIT TIME; JAUNDICE; LETTER; MALE; NAUSEA; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PREDICTION; RIGOR; STENT; BLOOD; DIFFERENTIAL DIAGNOSIS; POSTCHOLECYSTECTOMY SYNDROME; RECURRENT DISEASE;

ACUTE DISEASE; AGED; CA-19-9 ANTIGEN; CHOLANGITIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; POSTCHOLECYSTECTOMY SYNDROME; RECURRENCE; STENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 45149088155     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318170584b     Document Type: Letter

References (7)

1. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;84:350-355.
2. Craxi A, Patti C, Aragona E. Serum CA-19-9 levels in patient with hepatocellular carcinoma or cirrhosis. Ital J Gastroenterol 1985;17:288-289.
3. Magnani JL, Steplewski Z, Koprowski H, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5:957-971.
4. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA19-9. Clin Chem 1983;29:549-552.
5. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24:2897-2902.
6. Jee-Eun Kin, Kyu Taek Lee, et al. Clinical usefulness of carbohydrate antigen-19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-186.
7. Mayra S, Hilton G, Erin NM. Elevated CA 19-9 levels in a patient with Mirrizi's syndrome. South Med J 2006;99:160-163.